Valuation: XOMA Royalty Corporation

Market Cap 564M 495M 457M 422M 800M 54.04B 816M 5.49B 2.13B 26.44B 2.12B 2.07B 91.8B P/E 2026 *
57.2x
P/E 2027 * -900x
Enterprise Value 564M 495M 457M 422M 800M 54.04B 816M 5.49B 2.13B 26.44B 2.12B 2.07B 91.8B EV / Sales 2026 *
9.29x
EV / Sales 2027 * 10.7x
Free-Float
97.66%
Yield 2026 *
-
Yield 2027 * -
1 day+2.53%
1 week+5.58%
Current month+5.88%
1 month+7.35%
3 months+29.83%
6 months+50.40%
Current year+69.24%
1 week 42.9
Extreme 42.905
45.19
1 month 40.76
Extreme 40.76
45.19
Current year 22.29
Extreme 22.29
45.19
1 year 22.29
Extreme 22.29
45.19
3 years 13.48
Extreme 13.48
45.19
5 years 13.48
Extreme 13.48
45.19
10 years 3.96
Extreme 3.96
46.32
Manager TitleAgeSince
Chief Executive Officer 51 2022-12-31
Director of Finance/CFO 42 2026-01-11
Chief Investment Officer 45 2023-01-02
Director TitleAgeSince
Chairman 70 2024-01-06
Director/Board Member 72 2012-12-12
Director/Board Member 52 2017-02-15
Date Insider Type Main position Quantity % Market Cap.
05-20Free

Chairman

3,586 0.0296%
05-20Free

Director

3,586 0.0296%
05-20Other

Director

0 0%
Change 5-day change 1-year change 3-year change Capi.($)
+2.53%+5.58%+70.07%+169.62% 564M
-0.65%-3.16%+41.10%+63.12% 555M
+2.68%+0.35%-7.12%-14.33% 358M
-0.92%+0.36%-29.41%-35.89% 84.68M
Average +0.91%+1.19%+18.66%+45.63% 390.52M
Weighted average by Cap. +1.25%-0.09%+36.69%+78.48%

Financials

2026 *2027 *
Net sales 60.73M 53.27M 49.18M 45.45M 86.14M 5.82B 87.86M 591M 230M 2.85B 228M 223M 9.88B 52.5M 46.05M 42.51M 39.29M 74.46M 5.03B 75.95M 511M 199M 2.46B 197M 193M 8.54B
Net income 15.03M 13.19M 12.17M 11.25M 21.32M 1.44B 21.75M 146M 56.86M 704M 56.45M 55.22M 2.45B -900K -789K -729K -673K -1.28M -86.18M -1.3M -8.76M -3.4M -42.17M -3.38M -3.31M -146M
Net Debt - -
Logo XOMA Royalty Corporation
XOMA Royalty Corporation is a biotechnology royalty aggregator. The Company’s royalty aggregator business is primarily focused on early to mid-stage clinical assets, primarily in Phase I and II, with significant commercial sales potential that are licensed to funded partners. The Company has a portfolio of economic rights and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The Company's commercial assets include OJEMDA (tovorafenib), IXINITY, XACIATO, VABYSMO (faricimab svoa), DSUVIA (sufentanil sublingual tablet), and MIPLYFFA (arimoclomol). Its Phase III assets include Rilvegostomig (AZD2936), Ficlatuzumab (AV-299), Ovaprene, D-Fi (FCX-007), Seralutinib, Cetrelimab (JNJ-63723283), Ersodetug (RZ358), and Mezagitamab (TAK-079). Its Phase II assets include Acimtamig (AFM13), AFM24, Vosaroxin, Aldoxorubicin, G03-52-01, PBF-680, PBF-677, Vidutolimod (CMP-001), and RZ-402. Its others assets include COM902 and MT-0169.
Employees
14
Date Price Change Volume
26-07-08 US$45.00 +2.53% 255,335
26-07-07 US$43.89 +0.09% 144,744
26-07-06 US$43.85 +1.98% 209,109
26-07-02 US$43.00 +0.89% 137,659
26-07-01 US$42.62 +0.28% 124,640
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
3
Last Close Price
45.00USD
Average target price
39.00USD
Spread / Average Target
-13.33%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. XOMA Stock